Literature DB >> 6416281

Pharmacokinetics of the infusion of alfentanil in man.

R J Fragen, L H Booij, G J Braak, T B Vree, J Heykants, J F Crul.   

Abstract

The pharmacokinetics of alfentanil under the conditions of an empirically derived 1-h continuous infusion of 3 micrograms kg-1 min-1, with a bolus of 80 micrograms kg-1, both i.v., were determined in five patients. The distribution half-life (mean +/- SD) (7.4 +/- 3.1 min), elimination half-life (86.7 +/- 15.8 min), apparent volume of distribution, Varea (0.44 +/- 0.15 litre kg-1) and elimination clearance (3.33 +/- 0.75 ml kg-1 min-1) were similar to those previously reported for a single bolus of alfentanil. These values for apparent volume of distribution and clearance can be used to calculate correct bolus and infusion doses to maintain any desired steady state plasma concentration using standard formulae: for example, to maintain a steady state plasma concentration of 400 ng ml-1, a bolus dose of 176 micrograms kg-1 and an infusion of 1.3 micrograms kg-1 min1 would be required.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6416281     DOI: 10.1093/bja/55.11.1077

Source DB:  PubMed          Journal:  Br J Anaesth        ISSN: 0007-0912            Impact factor:   9.166


  4 in total

1.  Prediction of cytochrome p450-mediated hepatic drug clearance in neonates, infants and children : how accurate are available scaling methods?

Authors:  Sven Björkman
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

2.  Comparison of fentanyl, sufentanil and alfentanil during awake craniotomy for epilepsy.

Authors:  E Gignac; P H Manninen; A W Gelb
Journal:  Can J Anaesth       Date:  1993-05       Impact factor: 5.063

3.  Alfentanil pharmacokinetics in patients undergoing abdominal aortic surgery.

Authors:  R J Hudson; I R Thomson; P M Burgess; M Rosenbloom
Journal:  Can J Anaesth       Date:  1991-01       Impact factor: 5.063

4.  Alfentanil-midazolam anaesthesia has no electrophysiological effects upon the normal conduction system or accessory pathways in patients with Wolff-Parkinson-White syndrome.

Authors:  M D Sharpe; W B Dobkowski; J M Murkin; G Klein; G Guiraudon; R Yee
Journal:  Can J Anaesth       Date:  1992-10       Impact factor: 5.063

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.